Feasibility of Egg White Pudding Supplementation for Individuals in Personal Care Home Centres Needing Dietary Supplementation

NCT07805993 | Recruiting

• 1 other identifier: HS26476
• Study Type: interventional
• Target: 54
• Locations: 1 country
• Sites: 1

Brief Summary

This trial is an open-label randomized controlled parallel arm feasibility trial. 54 residents in care homes receiving nutrition supplementation (minimum 40% of each sex, ≥ 50 years of age). Participants will receive the egg white pudding (experimental) or a standard currently provided dietary supplement (control) on a daily basis and will be advised to follow any dietary recommendations they receive from their care team. Participants will be recruited at personal care homes throughout Winnipeg. Study visits will take place with a study coordinator at baseline and at 8 weeks (endpoint). Product acceptability will be assessed through dietary logs. This study has been reviewed and approved by The Committee for Harmonized Health Impact, Privacy, and Ethics Review (CHIPER).

Conditions

Sarcopenia in Elderly

Keywords

Protein; Feasibility; Older Adults; Home Care Centres; Sarcopenia; Canada; Manitoba; Protein Pudding; Egg White Pudding; Mini Nutritional Assessment

Outcome Measures

Primary Outcomes (1)

• Hand Grip Strength

  Hand grip strength will be measured using a specialized handheld device called a hand dynamometer that records the maximum isometric force generated in kilograms or pounds.

  8 weeks

Secondary Outcomes (3)

• Waist circumference

  8 weeks

• Body weight

  8 weeks

• Calf Circumference

  8 weeks

Study Arms (2)

Control

ACTIVE COMPARATOR

Resource 2.0

Dietary Supplement: Nestle Resource

Experimental

EXPERIMENTAL

Egg White Pudding

Dietary Supplement: Egg White Pudding

Interventions

Egg White Pudding DIETARY_SUPPLEMENT

Participants will be given a high protein egg white pudding 5 days a week for 8 weeks.

Experimental

Nestle Resource DIETARY_SUPPLEMENT

Participants in the control group will be given 180 ml of Resource 2.0 seven days a week for 8 weeks.

Control

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Residing in a partnering Personal Care Home
• Participant is willing and able to give informed consent for participation in the trial or has an ADM who is authorized to provide consent on their behalf.
• Male or female aged ≥50 years

You may not qualify if:

• Allergy to eggs
• Inability to consume treatment product
• Unable to provide written consent
• Unable to understand English
• Does not have an ADM

Sponsors & Collaborators

• Seven Oaks Hospital Chronic Disease Innovation Centre: lead

Study Sites (1)

The Saul and Claribel Simkin Centre

Winnipeg, Manitoba, Canada

RECRUITING

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Central Study Contacts

Navdeep Tangri, MD, PhD

CONTACT

204-631-3834; NTangri@sogh.mb.ca

Maryem Zahra, BA

CONTACT

204-631-3834; MZahra@sogh.mb.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 22, 2026
• First Posted: September 8, 2026
• Study Start: June 8, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): February 1, 2027
• Last Updated: September 8, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)